reports should include the words "Pfizer-BioNTech COVID-19 Vaccine EUA" 
      in the description section of the report 
 
   -- Vaccination providers should review the Fact Sheet for Information to 
      Provide to Vaccine Recipients/Caregivers and Mandatory Requirements for 
      Pfizer-BioNTech COVID-19 Vaccine Administration Under Emergency Use 
      Authorization 
 
 
   Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare 
Providers Administering Vaccine (Vaccination Providers) including Full 
EUA Prescribing Information available at www.cvdvaccine-us.com 
 
   About Pfizer: Breakthroughs That Change Patients' Lives 
 
   At Pfizer, we apply science and our global resources to bring therapies 
to people that extend and significantly improve their lives. We strive 
to set the standard for quality, safety and value in the discovery, 
development and manufacture of health care products, including 
innovative medicines and vaccines. Every day, Pfizer colleagues work 
across developed and emerging markets to advance wellness, prevention, 
treatments and cures that challenge the most feared diseases of our 
time. Consistent with our responsibility as one of the world's premier 
innovative biopharmaceutical companies, we collaborate with health care 
providers, governments and local communities to support and expand 
access to reliable, affordable health care around the world. For more 
than 150 years, we have worked to make a difference for all who rely on 
us. We routinely post information that may be important to investors on 
our website at 
https://www.globenewswire.com/Tracker?data=8vfqJLm5RQ1mJsIF-rMTplONXIHREqP84kfyDwgQnq2Ch9nF8UUzpUjg5aDe0hapxie-IGg09QqV6l4JHgW65g== 
www.Pfizer.com. In addition, to learn more, please visit us on 
https://www.globenewswire.com/Tracker?data=8vfqJLm5RQ1mJsIF-rMTpnXYp6ILwbaEKp5kOySsbe1XfzwoK6ZgigrlaAgiU84Uaet7PxIkJ-euzDGg335gTQ== 
www.Pfizer.com and follow us on Twitter at 
https://www.globenewswire.com/Tracker?data=ywyFQk23vtT8FRUHinFDFa-N6191QJbqw9JilYaLJBGtS0yJ-9abvT3cIBzY6OjbuqPHt6Abqc3DD1ABJdRIhg== 
@Pfizer and 
https://www.globenewswire.com/Tracker?data=ywyFQk23vtT8FRUHinFDFS4Gt6XJaTO2-jodV0RBk6ZtXeK7S0WDeZ7eBEjUQtBaArPPRpWaW9fpvB4UxA-fIW2DG-vZRLp9rLZ5QUJOn8o= 
@Pfizer News, 
https://www.globenewswire.com/Tracker?data=_THnMVnNgKvejBfo0ALwxANFH6nmWb3aHzyv8ebsHWmlpguJ6kkdLH_n3l335v5wg7Y5z1WF8XLgJjTOH8WFcTZMdtKnrw_Tpe4yyXyYAyY= 
LinkedIn, 
https://www.globenewswire.com/Tracker?data=oWP5l2gxURM2OQsQviptahFAPxH7A3G89-16e9Umnnw-0B0wtXzxos2YJIPSPPQ7BZ7_ABIOyyalUuU8PNcRZQ== 
YouTube and like us on Facebook at 
https://www.globenewswire.com/Tracker?data=c-bIHwFSbkdMfWBz3P3wn5TC4qEbSubDFpJ0cVlkrl_FAbjCXxnFVHrMt8lO9nhJ6wYV4lTU7R_Jtjj9gXllqXhVYHppQm4j_dVCUsyaWYw= 
Facebook.com/Pfizer. 
 
   Pfizer Disclosure Notice 
 
   The information contained in this release is as of February 25, 2021. 
Pfizer assumes no obligation to update forward-looking statements 
contained in this release as the result of new information or future 
events or developments. 
 
   This release contains forward-looking information about Pfizer's efforts 
to combat COVID-19, the collaboration between BioNTech and Pfizer to 
develop a COVID-19 vaccine, the BNT162 mRNA vaccine program, the mRNA 
platform and regulatory pathway and the Pfizer-BioNTech COVID-19 Vaccine 
(BNT162b2) (including qualitative assessments of available data, 
potential benefits, a potential booster dose and a potential new 
variant-specific vaccine, expectations for clinical trials, the 
anticipated timing of regulatory submissions, regulatory approvals or 
authorizations and anticipated manufacturing, distribution and supply) 
involving substantial risks and uncertainties that could cause actual 
results to differ materially from those expressed or implied by such 
statements. Risks and uncertainties include, among other things, the 
uncertainties inherent in research and development, including the 
ability to meet anticipated clinical endpoints, commencement and/or 
completion dates for clinical trials, regulatory submission dates, 
regulatory approval dates and/or launch dates, as well as risks 
associated with preclinical and clinical data (including the in vitro 
and Phase 3 data), including the possibility of unfavorable new 
preclinical, clinical or safety data and further analyses of existing 
preclinical, clinical or safety data; the ability to produce comparable 
clinical or other results, including the rate of vaccine effectiveness 
and safety and tolerability profile observed to date, in additional 
analyses of the Phase 3 trial and additional studies or in larger, more 
diverse populations upon commercialization; the ability of BNT162b2 to 
prevent COVID-19 caused by emerging virus variants; the risk that more 
widespread use of the vaccine will lead to new information about 
efficacy, safety, or other developments, including the risk of 
additional adverse reactions, some of which may be serious; the risk 
that preclinical and clinical trial data are subject to differing 
interpretations and assessments, including during the peer 
review/publication process, in the scientific community generally, and 
by regulatory authorities; whether and when additional data from the 
BNT162 mRNA vaccine program will be published in scientific journal 
publications and, if so, when and with what modifications and 
interpretations; whether regulatory authorities will be satisfied with 
the design of and results from these and any future preclinical and 
clinical studies; whether and when a Biologics License Application for 
BNT162b2 may be filed in the U.S. and whether and when other biologics 
license and/or emergency use authorization applications may be filed in 
particular jurisdictions for BNT162b2 or any other potential vaccines 
that may arise from the BNT162 program, and if obtained, whether or when 
such emergency use authorization or licenses will expire or terminate; 
whether and when any applications that may be pending or filed for 
BNT162b2 (including a potential Biologics License Application in the 
U.S.) or other vaccines that may result from the BNT162 program may be 
approved by particular regulatory authorities, which will depend on 
myriad factors, including making a determination as to whether the 
vaccine's benefits outweigh its known risks and determination of the 
vaccine's efficacy and, if approved, whether it will be commercially 
successful; decisions by regulatory authorities impacting labeling or 
marketing, manufacturing processes, safety and/or other matters that 
could affect the availability or commercial potential of a vaccine, 
including development of products or therapies by other companies; 
disruptions in the relationships between us and our collaboration 
partners or third-party suppliers; risks related to the availability of 
raw materials to manufacture a vaccine; challenges related to our 
vaccine's ultra-low temperature formulation, two-dose schedule and 
attendant storage, distribution and administration requirements, 
including risks related to storage and handling after delivery by 
Pfizer; the risk that we may not be able to successfully develop other 
vaccine formulations; the risk that we may not be able to create or 
scale up manufacturing capacity on a timely basis or maintain access to 
logistics or supply channels commensurate with global demand for our 
vaccine, which would negatively impact our ability to supply the 
estimated numbers of doses of our vaccine within the projected time 
periods as previously indicated; whether and when additional supply 
agreements will be reached; uncertainties regarding the ability to 
obtain recommendations from vaccine technical committees and other 
public health authorities and uncertainties regarding the commercial 
impact of any such recommendations; uncertainties regarding the impact 
of COVID-19 on Pfizer's business, operations and financial results; and 
competitive developments. 
 
   A further description of risks and uncertainties can be found in 
Pfizer's Annual Report on Form 10-K for the fiscal year ended December 
31, 2019 and in its subsequent reports on Form 10-Q, including in the 
sections thereof captioned "Risk Factors" and "Forward-Looking 
Information and Factors That May Affect Future Results", as well as in 
its subsequent reports on Form 8-K, all of which are filed with the U.S. 
Securities and Exchange Commission and available at www.sec.gov and 
https://www.globenewswire.com/Tracker?data=8vfqJLm5RQ1mJsIF-rMTpr_5iNft8NN5kmu514-xu6CUY_lWWy_he-w90eZJ85ICswxyQvRvJV-Qtg6hygSbFw== 
www.pfizer.com. 
 
   About BioNTech 
 
   Biopharmaceutical New Technologies is a next generation immunotherapy 
company pioneering novel therapies for cancer and other serious 
diseases. The Company exploits a wide array of computational discovery 
and therapeutic drug platforms for the rapid development of novel 
biopharmaceuticals. Its broad portfolio of oncology product candidates 
includes individualized and off-the-shelf mRNA-based therapies, 
innovative chimeric antigen receptor T cells, bi-specific checkpoint 
immuno-modulators, targeted cancer antibodies and small molecules. Based 
on its deep expertise in mRNA vaccine development and in-house 
manufacturing capabilities, BioNTech and its collaborators are 
developing multiple mRNA vaccine candidates for a range of infectious 
diseases alongside its diverse oncology pipeline. BioNTech has 
established a broad set of relationships with multiple global 
pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal 
Health, Genentech, a member of the Roche Group, Regeneron, Genevant, 
Fosun Pharma, and Pfizer. For more information, please visit 
https://www.globenewswire.com/Tracker?data=8vfqJLm5RQ1mJsIF-rMTpr0qDj2W2d2VZKypVvi5UT0V4-zwn1JuftCpvbf08l7SHOwZnUWPa60Sc3ddCoaiuA== 
www.BioNTech.de. 
 
   BioNTech Forward-looking Statements 
 
   This press release contains "forward-looking statements" of BioNTech 
within the meaning of the Private Securities Litigation Reform Act of 
1995. These forward-looking statements may include, but may not be

(MORE TO FOLLOW) Dow Jones Newswires

February 25, 2021 06:45 ET (11:45 GMT)